Replies to post #111370 on Biotech Values

[exwannabe]

Re:

Do you feel that this modification was made for any other purpose tha to increase MIT's "cut" of MNTA's share of m-Lovenox's profits?

It would make no sense to just give MIT either more or less.

I would assume that the new deal slightly "de-risks" the MNTA side. So MIT will come out better IF mL stays sole generic, but MNTA saves money if tL gets approved.

Of course, w/o the numbers we are guessing.

[DewDiligence]

CFO, Rick Shea, has publicly stated that MIT’s royalty is de minimis in the overall scheme of things. This is presumably the reason MNTA did not deem it necessary to issue a PR to announce the changes to the agreement with MIT.